StudyFinder

A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult atypical hemolytic uremic syndrome (aHUS) patients who are naive to complement inhibitor therapy

Recruiting

To evaluate the efficacy and safety of iptacopan at a dose of 200 mg twice a day for 52 weeks in patients with atypical hemolytic uremic syndrome (aHUS).

I'm interested

Male or Female
18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• evidence of active Thrombotic Microangiopathy (TMA)
Exclusion Criteria:

• previous or ongoing treatment with complement inhibitors, including anti-C5 antibody
• ADAMTS13 deficiency
• positive test for Shiga toxin * direct Coombs test
• had a bone marrow transplant or hematopoietic stem cell transplant, or a heart, lung, small bowel, pancreas or live transplant

Drug: Iptacopan

Blood Disorders, Kidney, Prostate & Urinary, Rare Diseases

Clinics and Surgery Center (CSC)

Karen Omlung - seve0024@umn.edu
Nattawat Klomjit
PHASE3
STUDY00020503
See this study on ClinicalTrials.gov

Back